SuperworthDenali Therapeutics shares outstanding DNLI
Diluted shares outstanding, averaged over each quarter, from 2017.
- Latest quarter, to Jun 30, 2026
- 187.3M
- On a year earlier
- +9.3%
- more shares
Denali Therapeutics had 187.3M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 9.3% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 175.5M | +3% |
| FY2024 | 170.1M | +23% |
| FY2023 | 138.2M | +4% |
| FY2022 | 132.9M | +9% |
| FY2021 | 122.2M | −1% |
| FY2020 | 123.9M | +29% |
| FY2019 | 96.1M | +2% |
| FY2018 | 94.3M | +207% |
| FY2017 | 30.8M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 187.3M | +9% | |
| Q1 FY26 | 186.6M | +9% | |
| Q4 FY25 | 175.5M | +3% | |
| Q3 FY25 | 172.4M | +2% | |
| Q2 FY25 | 171.4M | +2% | |
| Q1 FY25 | 171.2M | +15% | |
| Q4 FY24 | 170.1M | +23% | |
| Q3 FY24 | 169.5M | +23% | |
| Q2 FY24 | 168.8M | +20% | |
| Q1 FY24 | 149.4M | +9% | |
| Q4 FY23 | 138.2M | +4% | |
| Q3 FY23 | 137.6M | +11% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Denali Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.